Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Duke-nus Medical School
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jul 25, 2024
Discovery & Translation
Science Spotlight: Delivering full-length dystrophin, intracellular bioPROTACs, and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Dec 17, 2022
Discovery & Translation
Synthetic engineering of immune cells; plus Genentech’s bispecific for Netherton and more
BioCentury’s roundup of translational news
BioCentury | Jun 17, 2022
Discovery & Translation
Scalable method to measure SARS-CoV-2 T cell immunity; plus therapies from NeoImmune, Exavir and more
BioCentury’s roundup of translational news
BioCentury | Oct 4, 2021
Regulation
Tatsuya Kondo, architect of Japan’s PMDA, dead at 79
A neurosurgeon by training, Kondo transformed how drugs are regulated in Japan
BioCentury | Dec 29, 2020
Product Development
Arcturus undeterred by low neutralizing titers from COVID vaccine in Phase I; shares slide
Arcturus believes cellular responses induced by its COVID-19 vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data. The RNA
BioCentury | Jul 17, 2020
Product Development
Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei
BioCentury | Jun 11, 2020
Product Development
Emerging COVID-19 serology tests aim for neutralizing antibodies
New COVID-19 serology tests focus on the antibodies believed most likely to block viral entry
BioCentury | May 21, 2020
Product Development
Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine
Chronic disease focus teed up company’s capacity to make hundreds of millions of doses of mRNA vaccine
BioCentury | Apr 25, 2020
Product Development
Mesoblast’s stem cells boost survival to 83% in COVID-19 patients with ARDS; Arch also taking aim at respiratory distress
Duke-NUS reveals new serological test
Items per page:
1 - 10 of 29